Protect your patients’ path toward remission
The National Cancer Comprehensive Network® (NCCN) recommendation for G-CSF use during chemotherapy
From NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®):
G-CSF (eg, pegfilgrastim) primary prophylaxis supports optimal dose intensity and clinical outcomes in patients undergoing chemotherapy.1
When FN risk is >20%, G-CSF prophylaxis*1:
Reduced the risk of FN1
(RR: 0.54; 95% CI, 0.43–0.67)
Significantly improved the relative dose intensity (RDI) of chemotherapy with an average difference in RDI of 8.4%1
(G-CSF-treated patients vs non-G-CSF-treated patients)
G-CSF was shown to increase RDI and is associated with survival benefit†1
*Results from a systematic review of 17 randomized trials, which included 3493 patients with solid tumors and lymphoma. G-CSF included filgrastim and pegfilgrastim.
†Survival benefit not included in UDENYCA® prescribing information.
CI = confidence interval; FN = febrile neutropenia; G-CSF = granulocyte colony stimulating factor; RR = relative risk.
Returning to the clinic to receive UDENYCA® may increase patient comfort.2See patient survey results
UDENYCA® delivers the reliable outcomes you expect, but with 35% cost savings per dose vs Neulasta®.*5Discover the value of UDENYCA®
UDENYCA® was confirmed to be highly similar to Neulasta®, with no clinically meaningful differences.2-4View proven biosimilarity
* Based on wholesale acquisition cost (WAC). WAC does not necessarily reflect actual prices paid by consumers, pharmacies, or third-party payers. UDENYCA® WAC of $4175 per prefilled syringe vs Neulasta® WAC of $6417 per prefilled syringe.
References: 1. Kuderer, M. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia. J Clin Oncol. 2007; 25(21):1-10 2. Data on file. Coherus BioSciences, Inc.; 2021. 3. UDENYCA® (pegfilgrastim-cbqv) package insert. Redwood City, CA: Coherus BioSciences, Inc.; 2021. 4. Neulasta® (pegfilgrastim) package insert. Thousand Oaks, CA: Amgen Inc.; 2021. 5. Data on file. Coherus BioSciences, Inc.; 2022.